EVAX Q4 2024 Earnings — Evaxion Biotech A/S Revenue & Financial Results | Market Cap Arena

EVAXEvaxion Biotech A/S

$20M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$122,000+67.1% YoY

Gross Profit

$122,000100.0% margin

Operating Income

-$4M-3298.4% margin

Net Income

-$4M-2974.6% margin

EPS (Diluted)

$-3.40

QoQ Revenue Growth

-96.0%

Cash Flow

Operating Cash Flow

$0

Free Cash Flow

$0

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$12M

Total Liabilities

$14M

Stockholders' Equity

-$2M

Cash & Equivalents

$5M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$122,000	$73,000	+67.1%
Gross Profit	$122,000	$73,000	+67.1%
Operating Income	-$4M	-$4M	+7.8%
Net Income	-$4M	-$5M	+19.8%